Inhibited Female Orgasm disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: INH003 MIFTS: 25	Inhibited Female Orgasm Categories: Reproductive diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Inhibited Female Orgasm

MalaCards integrated aliases for Inhibited Female Orgasm:

Name: Inhibited Female Orgasm ¹² ¹⁵

Female Orgasmic Disorder ¹² ⁷¹

Classifications:

MalaCards categories:
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:7518

ICD9CM ³⁴ 302.73

NCIt ⁴⁹ C34958

SNOMED-CT ⁶⁷ 60103007

ICD10 ³² F52.31

UMLS ⁷¹ C0033948

Sources

Summaries for Inhibited Female Orgasm

MalaCards based summary : Inhibited Female Orgasm, also known as female orgasmic disorder, is related to hypoactive sexual desire disorder and sexual disorder. An important gene associated with Inhibited Female Orgasm is IDH3G (Isocitrate Dehydrogenase (NAD(+)) 3 Non-Catalytic Subunit Gamma), and among its related pathways/superpathways are Pyruvate metabolism and Citric Acid (TCA) cycle and Citrate cycle (TCA cycle). The drugs Dopamine and Bupropion have been mentioned in the context of this disorder. Affiliated tissues include breast.

Sources

Related Diseases for Inhibited Female Orgasm

Diseases related to Inhibited Female Orgasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 36)

#	Related Disease	Score	Top Affiliating Genes
1	hypoactive sexual desire disorder	29.7	SHBG PRL
2	sexual disorder	29.0	SHBG PRL EHD4
3	d-2-hydroxyglutaric aciduria 1	10.1	IDH3G IDH3A
4	2-hydroxyglutaric aciduria	10.1	IDH3G IDH3A
5	psychosexual disorder	9.8	SHBG PRL
6	estrogen excess	9.8	SHBG PRL
7	steroid inherited metabolic disorder	9.8	SHBG PRL
8	androgenic alopecia	9.8	SHBG PRL
9	alopecia	9.8	SHBG PRL
10	pelvic varices	9.8	SHBG PRL
11	sebaceous gland disease	9.7	SHBG PRL
12	uterine benign neoplasm	9.7	SHBG PRL
13	reproductive organ benign neoplasm	9.7	SHBG PRL
14	acanthosis nigricans	9.7	SHBG PRL
15	anovulation	9.7	SHBG PRL
16	gynecomastia	9.7	SHBG PRL
17	varicocele	9.7	SHBG PRL
18	disorders of sexual development	9.7	SHBG PRL
19	impotence	9.7	SHBG PRL
20	lipoid congenital adrenal hyperplasia	9.7	SHBG PRL
21	hyperprolactinemia	9.7	SHBG PRL
22	insulin-like growth factor i	9.7	SHBG PRL
23	amenorrhea	9.7	SHBG PRL
24	hyperandrogenism	9.7	SHBG PRL
25	thyroid gland disease	9.7	SHBG PRL
26	goiter	9.7	SHBG PRL
27	turner syndrome	9.6	SHBG PRL
28	hypopituitarism	9.6	SHBG PRL
29	congenital hypothyroidism	9.6	SHBG PRL
30	hyperthyroidism	9.6	SHBG PRL
31	acromegaly	9.6	SHBG PRL
32	anorexia nervosa	9.6	SHBG PRL
33	premature ovarian failure 1	9.5	SHBG PRL
34	cryptorchidism, unilateral or bilateral	9.5	SHBG PRL
35	focal epilepsy	9.4	SHBG PRL
36	polycystic ovary syndrome	9.2	SHBG PRL

Graphical network of the top 20 diseases related to Inhibited Female Orgasm:

Sources

Symptoms & Phenotypes for Inhibited Female Orgasm

Sources

Drugs & Therapeutics for Inhibited Female Orgasm

Drugs for Inhibited Female Orgasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 12)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Dopamine

Approved

Phase 2, Phase 3

51-61-6, 62-31-7

681

Synonyms:

(3H)-Dopamine

.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane

.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride

1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)

1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride

1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium

153C5321-5FEE-4B0B-8925-F388F0EEEBD1

2-(3,4-dihydroxyphenyl)ethylamine

2-(3,4-Dihydroxyphenyl)ethylamine

2-benzenediol

3,4 Dihydroxyphenethylamine

3,4-dihydroxyphenethylamine

3,4-Dihydroxyphenethylamine

3,4-Dihydroxyphenethylamine hydrochloride

3,4-Dihydroxyphenylethylamine

3-Hydroxtyramine

3-Hydroxytyramine

3-Hydroxytyramine Hydrobromide

3-Hydroxytyramine hydrochloride

4-(2-Aminoethyl)-1,

4-(2-aminoethyl)-1,2-benzenediol

4-(2-Aminoethyl)-1,2-benzenediol

4-(2-Aminoethyl)-1,2-bezenediol

4-(2-Aminoethyl)benzene-1,2-diol

4-(2-aminoethyl)catechol

4-(2-Aminoethyl)catechol

4-(2-aminoethyl)pyrocatechol

4-(2-aminoethyl)-pyrocatechol

4-(2-Aminoethyl)pyrocatechol

4-(2-Aminoethyl)-pyrocatechol

4-(2-Aminoethyl)pyrocatechol hydrochloride

50444-17-2

51-61-6

62-31-7 (HYDROCHLORIDE)

a-(3,4-Dihydroxyphenyl)-b-aminoethane

AC1L19S5

AC1Q54AX

AC1Q54AY

AKOS003790978

alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane

ASL 279

BIDD:ER0506

Biomol-NT_000001

BPBio1_001123

BSPBio_001932

C03758

CHEBI:18243

CHEMBL59

CID681

cMAP_000036

cMAP_000065

D07870

DB00988

Deoxyepinephrine

DivK1c_000780

Dopamin

Dopamina

Dopamina [INN-Spanish]

dopamine

Dopamine

Dopamine (INN)

Dopamine (USAN)(*hydrochloride*)

Dopamine [INN:BAN]

Dopamine hydrochloride

Dopaminum

Dopaminum [INN-Latin]

Dopastat

Dophamine

Dynatra

EINECS 200-110-0

HSDB 3068

Hydrochloride, dopamine

Hydroxytyramin

hydroxytyramine

Hydroxytyramine

IDI1_000780

intropin

Intropin

Intropin [*hydrochloride*]

IP 498

KBio1_000780

KBio2_001492

KBio2_002388

KBio2_002484

KBio2_004060

KBio2_004956

KBio2_005052

KBio2_006628

KBio2_007524

KBio2_007620

KBio3_001152

KBio3_002867

KBio3_002962

KBioGR_001129

KBioGR_002388

KBioGR_002484

KBioSS_001492

KBioSS_002393

KBioSS_002491

KW-3-060

L000232

L-DOPAMINE

LDP

Lopac0_000586

Lopac-H-8502

LS-159

Medopa (TN)

m-Hydroxytyramine hydrochloride

MolPort-001-641-000

NCGC00015519-01

NCGC00015519-08

NCGC00096050-01

NCGC00096050-02

NCGC00096050-03

NCGC00096050-04

NCGC00096050-05

nchembio.105-comp9

nchembio.107-comp4

nchembio.284-comp1

nchembio.78-comp16

nchembio.89-comp3

nchembio705-8

nchembio801-comp8

NINDS_000780

NSC 173182

NSC169105

NSC173182

Oprea1_088821

Oxytyramine

Pyrocatechol, 4-(2-aminoethyl)- (8CI)

Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride

Revimine

Revivan

SPBio_001205

Spectrum_001012

SPECTRUM1505155

Spectrum2_001023

Spectrum3_000406

Spectrum4_000525

Spectrum5_000945

ST048774

STK301601

UNII-VTD58H1Z2X

UPCMLD0ENAT5885989:001

Bupropion

Approved

Phase 2, Phase 3

34911-55-2, 34841-39-9

444

Synonyms:

( -)-2-(tert-Butylamino)-3'-chloropropiophenone

( -)-2-(tert-Butylamino)-3'-chlorpropiophenon

(+-)-1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone

(+-)-1-(3-Chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone

(+-)-Bupropion

.alpha.-(tert-Butylamino)-m-chloropropiophenone

1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]propan-1-one

2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one

2-(Tert-Butylamino)-3'-chloropropiophenone

34841-36-6 (hydrochloride)

34841-39-9

34911-55-2

AB00053756

AC-197

AC1L198Y

alpha-(tert-butylamino)-m-chloropropiophenone

Amfebutamon

Amfebutamona

Amfebutamona [INN-Spanish]

Amfebutamone

AMFEBUTAMONE HCl

amfebutamonum

Amfebutamonum

Amfebutamonum [INN-Latin]

BPBio1_000042

BRD-A05186015-003-05-7

BRN 2101062

BSPBio_000038

BSPBio_002247

bupropion

Bupropion

Bupropion (INN)

Bupropion (Old RN)

Bupropion (USAN)

Bupropion [INN:BAN]

Bupropion Hcl

Bupropion hydrochloride

Bupropion hydrochloride, (+-)-isomer

Bupropion hydrocloride

Bupropion SR

Bupropion, (+-)-isomer

C06860

CHEBI:3219

CHEMBL894

CID444

CPD000472526

D07591

DB01156

DivK1c_007050

Elont

Esteve brand OF bupropion hydrochloride

glaxo Wellcome brand 1 OF bupropion hydrochloride

glaxo Wellcome brand 2 OF bupropion hydrochloride

glaxo Wellcome brand 3 OF bupropion hydrochloride

GlaxoSmithKline brand 1 OF bupropion hydrochloride

GlaxoSmithKline brand 2 OF bupropion hydrochloride

HMS2051G10

HMS2089G14

Jsp006301

KBio1_001994

KBio2_002143

KBio2_004711

KBio2_007279

KBio3_001467

KBioGR_001168

KBioSS_002143

L000725

Lopac0_000166

LS-122817

MLS001424015

MolPort-003-845-432

NCGC00015122-06

NCGC00089751-02

NCI60_002714

NSC315851

Prestwick0_000249

Prestwick1_000249

Prestwick2_000249

Prestwick3_000249

Quomen

SAM001246699

SMR000472526

SPBio_001817

SPBio_002257

SpecPlus_000954

Spectrum_001663

Spectrum2_001659

Spectrum3_000644

Spectrum4_000614

Spectrum5_001406

TL8002604

UNII-01ZG3TPX31

Wellbatrin

Wellbutrin

Wellbutrin SR

Wellbutrin XL

Zyban

Zyban (anti-smoking)

Zyntabac

Antidepressive Agents

Phase 2, Phase 3

Dopamine Agents

Phase 2, Phase 3

Cytochrome P-450 Enzyme Inhibitors

Phase 2, Phase 3

Psychotropic Drugs

Phase 2, Phase 3

Neurotransmitter Agents

Phase 2, Phase 3

Paroxetine

Approved, Investigational

Phase 2

61869-08-7

43815

Synonyms:

(−)-(3S,4R)-4-(p-fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine

(-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine

(-)-(3S,4R)-4-(P-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine

(-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-methylenedioxy)phenoxy)methyl)piperidine

(-)-Paroxetine

(-)-trans-4-(4-Fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)piperidine

(-)-trans-4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl]-piperidine

(3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine

(3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine

(3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine

(3S-trans)-3-((1,3-Benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine

(3S-trans)-3-[(1,3-Benzodioxol-5-yl-oxy)methyl]-4-(4-fluorophenyl)piperidine

[3H]Paroxetine

110429-35-1

3-(Benzo[1,3]Dioxol-5-Yl-Oxymethyl)-4-(4-Fluoro-Phenyl)-Piperidine Hydrochloride

61869-08-7

63952-24-9

64006-44-6 (maleate)

78246-49-8 (hydrochloride)

AB00514724

AC1L2AKL

AC1Q1H18

AC1Q4LV6

Acetate, paroxetine

Anhydrous, paroxetine hydrochloride

Aropax

BIDD:GT0673

BPBio1_000949

BRD-K37991163-003-02-7

BRL 29060

BRL-29060

BSPBio_000861

C07415

C19H20FNO3

Casbol

CHEBI:7936

CHEMBL490

CID43815

D02362

DB00715

DivK1c_006884

FG 7051

FG-7051

Frosinor

FT-0085087

Hemihydrate paroxetine hydrochloride

Hemihydrate, paroxetine hydrochloride

HMS2090H05

Hydrochloride anhydrous, paroxetine

Hydrochloride hemihydrate, paroxetine

Hydrochloride, hemihydrate paroxetine

Hydrochloride, paroxetine

I14-7752

KBio1_001828

KBio2_002232

KBio2_004800

KBio2_007368

KBioSS_002232

LS-114249

Maleate, paroxetine

MolPort-003-849-791

Motivan

NCGC00025355-02

NCGC00025355-03

NCGC00025355-04

NCGC00025355-05

NCGC00025355-06

NCGC00025355-07

NCGC00025355-08

NNC-20-7051

Paroxetina

Paroxetina [INN-Spanish]

paroxetine

Paroxetine

Paroxetine (TN)

Paroxetine (USP/INN)

Paroxetine [USAN:INN:BAN]

Paroxetine acetate

Paroxetine Hcl

Paroxetine hydrochloride

Paroxetine hydrochloride anhydrous

Paroxetine hydrochloride hemihydrate

Paroxetine hydrochloride, hemihydrate

Paroxetine maleate

Paroxetine, cis-(-)-isomer

Paroxetine, cis-(+)-isomer

Paroxetine, trans-(+)-isomer

Paroxetinum

Paroxetinum [INN-Latin]

Paxetil

Paxil

Paxil CR

PaxPar

Pexeva

Prestwick3_000851

Seroxat

Seroxat CR

SpecPlus_000788

Spectrum_001752

Spectrum5_001665

TL8003967

UNII-41VRH5220H

Fluoxetine

Approved, Vet_approved

Phase 2

54910-89-3

3386

Synonyms:

(+) or (-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine

(+) or (-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine

(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine

(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine

(+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine

(+/-)-Fluoxetine

(+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine

(+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine

(+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine

(+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]

(+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine

3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine

52341-67-0

54910-89-3

57226-07-0

59333-67-4 (hydrochloride)

AB00053774

AC-14564

AC1L1FTH

Adofen

AKOS003663021

Animex-On

Bio-0787

Biomol-NT_000152

BPBio1_000354

BPBio1_000509

BRD-A31159102-001-01-9

BRD-A31159102-003-05-6

BSPBio_000461

BSPBio_003375

C17H18F3NO

CHEBI:5118

CHEMBL41

CID3386

D00326

DB00472

Deprex

DivK1c_006819

dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine

Eufor

Floxetine

Fluctin

Fluoxeren

Fluoxetin

Fluoxetina

Fluoxetina [INN-Spanish]

Fluoxetina [Spanish]

fluoxetine

Fluoxetine

Fluoxétine

fluoxetine (Prozac)

Fluoxetine (TN)

Fluoxetine (USAN/INN)

Fluoxetine [USAN:INN:BAN]

Fluoxetine Hcl

Fluoxetine hydrochloride

Fluoxetine Hydrochloride

Fluoxetinum

Fluoxetinum [INN-Latin]

Fluval

Fontex

Foxetin

HMS2090H14

KBio1_001763

KBio2_002159

KBio2_004727

KBio2_007295

KBio3_002595

KBioGR_001166

KBioSS_002159

L000931

Lilly-110140

Lopac0_000558

LS-31040

Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine

Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine

MolPort-001-683-482

NCGC00015428-10

NCGC00024879-03

NCGC00024879-04

nchembio.534-comp2

N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine

N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine

N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine

N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine

NSC283480

Portal

Prestwick0_000511

Prestwick1_000511

Prestwick2_000511

Prestwick3_000511

Prozac

Prozac Weekly

Pulvules

Reconcile

Reneuron

Sarafem

SPBio_001815

SPBio_002382

SpecPlus_000723

Spectrum_001679

Spectrum2_001658

Spectrum3_001648

Spectrum4_000613

Spectrum5_001518

STK734483

Symbyax

TL8003595

UNII-01K63SUP8D

Sertraline

Approved

Phase 2

79617-96-2

68617

Synonyms:

(+)-Sertraline

(1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine

(1S,4S)-sertraline

(1S,4S)-Sertraline

(1S-cis)-1,2,3,4-tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine

(1S-cis)-1,2,3,4-tetrahydro-4-(3,4-Dichlorophenyl)-N-methyl-1-naphthalenamine

(1S-cis)-1,2,3,4-Tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine

(1S-cis)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine

79559-97-0 (Hydrochloride)

79617-96-2

AB00514002

AB1004870

AC-15639

AC1L2A41

AC1Q3O5N

AC1Q3XJU

Altruline

apo Sertraline

apo-Sertraline

Apo-Sertraline

Apotex brand OF sertraline hydrochloride

Aremis

Besitran

BIDD:GT0768

BIDD:PXR0193

Boehringer ingelheim brand OF sertraline hydrochloride

BPBio1_001285

BRD-K82036761-003-02-1

BRN 5753709

BSPBio_001167

BSPBio_002698

C07246

C17H17Cl2N

CHEBI:9123

CHEMBL809

CID68617

cis-(+)-sertraline

cis-(+)-Sertraline

Cp 51974

CP 51974

D02360

DB01104

DB08567

Esteve brand OF sertraline hydrochloride

FT-0081122

Gen sertraline

Genpharm brand OF sertraline hydrochloride

Gen-sertraline

Gladem

HSDB 7037

Hydrochloride, sertraline

KBio3_001918

KBioGR_001724

Lacer brand OF sertraline hydrochloride

LS-94179

Lustral

MLS001195647

MLS002222308

MolPort-002-885-860

NCGC00092386-03

NCGC00092386-04

NCGC00092386-05

NCGC00092386-06

NCGC00092386-07

NCGC00092386-08

NCGC00092386-09

novo Sertraline

Novopharm brand OF sertraline hydrochloride

novo-Sertraline

Parke davis brand OF sertraline hydrochloride

Pfizer brand OF sertraline hydrochloride

Prestwick3_001014

ratio Sertraline

Ratiopharm brand OF sertraline hydrochloride

ratio-Sertraline

Rhoxal sertraline

Rhoxalpharma brand OF sertraline hydrochloride

Rhoxal-sertraline

Roerig brand OF sertraline hydrochloride

Sealdin

Sertralina

Sertralina [Spanish]

sertraline

Sertraline

Sertraline (INN)

sertraline (Zoloft)

Sertraline [INN:BAN]

Sertraline [Zoloft]

Sertraline hydrochloride

Sertraline Hydrochloride

Sertraline hydrochloride (1S-cis)-isomer

Sertralinum

Sertralinum [Latin]

SMR000596516

SPBio_000385

Spectrum2_000493

Spectrum3_001079

Spectrum4_001232

SRE

Sultamicillin Tosylate

UNII-QUC7NX6WMB

Zoloft

Testosterone

Approved, Experimental, Investigational

Phase 2

58-22-0, 481-30-1

10204 6013

Synonyms:

(17-alpha)-17-Hydroxyandrost-4-en-3-one

(17beta)-17-Hydroxyandrost-4-en-3-one

(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one

17 alpha Testosterone

17?-Hydroxy-4-androsten-3-one

17a-cis-Testosterone

17alpha-cis-Testosterone

17-alpha-Hydroxyandrost-4-en-3-one

17-alpha-Testosterone

17beta-Hydroxy-3-oxo-4-androstene

17beta-hydroxy-4-androsten-3-one

17beta-Hydroxy-4-androsten-3-one

17beta-Hydroxyandrost-4-en-3-one

17-beta-Hydroxyandrost-4-en-3-one

17beta-Hydroxyandrost-4-ene-3-one

17-beta-Hydroxy-delta(sup 4)-androsten-3-one

17beta-Hydroxy-delta(sup4)-androsten-3-one

17b-hydroxy-4-androsten-3-one

17-Epitestosterone

17-Hydroxy-(17beta)-androst-4-en-3-one

17-Hydroxy-(17-beta)-androst-4-en-3-one

46923_FLUKA

46923_RIEDEL

4-Androsten-17?-ol-3-one

4-Androsten-17beta-ol-3-one

4-androsten-17β-ol-3-one

4-androstene-17beta-ol-3-one

58-22-0

7-beta-Hydroxyandrost-4-en-3-one

AA 2500

AC-14899

AC1L1LM0

Andriol

Andro

Andro 100

Andro L.A. 200

Androderm

Androderm (TN)

Androgel

AndroGel

Androgel (TN)

Android 10

Android 25

Android 5

Androlin

Andronaq

Andronate 100

Andronate 200

Andropatch

Andropository 200

Androsorb

Androst-4-en-17beta-ol-3-one

Andrusol

Andryl 200

B5DEE83F-632B-48A1-A0ED-A51E7F13DF2E

beta testosterone

Beta Testosterone

BIDD:ER0555

BIM-0061761.0001

Bio-0678

Bio-T-Gel

C00535

CCRIS 574

CDB 111C

CHEBI:17347

CHEMBL386630

CID6013

cis-Testosterone

CMC_13449

COL 1621

CP 601B

CPD000058344

Cristerona T

Cristerone T

D00075

DB00624

Dea No. 4000

Delatest

Delatestryl

delta(sup 4)-Androsten-17(beta)-ol-3-one

delta4-Androsten-17beta-ol-3-one

delta4-androsten-17b-ol-3-one

Depotest

Depo-Testosterone

Depo-Testosterone Cypionate

EINECS 200-370-5

Epi-testosterone

Everone 200

Geno-cristaux gremy

Geno-Cristaux Gremy

Halotensin

HMS2052N11

Homosteron

Homosterone

HSDB 3398

Intrinsa

Isotestosterone

Libigel

LibiGel

LMST02020002

LS-148813

Malerone

Malestrone

Malestrone (amps)

Malogen in Oil

Malogen, aquaspension injection

Malogen, Aquaspension Injection

Mertestate

Metandren

Methyltestosterone

MLS000563091

MLS001032098

MLS001306401

MLS002174283

MolPort-002-506-901

NCGC00091018-01

Neo-Hombreol F

Neotestis

Neo-testis

Neo-Testis

NSC 9700

Oreton

Oreton F

Oreton Methyl

Oreton-F

Orquisteron

Perandren

Percutacrine androgenique

Percutacrine Androgenique

Primotest

Primoteston

Relibra

S00309

S2033_Selleck

SAM001246921

Scheinpharm Testone-Cyp

SMR000058344

SMR001261453

Striant

Striant (TN)

Sustanon

Sustanone

Sustason 250

Synandrol F

T1500_SIGMA

T5411_FLUKA

T5411_SIGMA

T-Cypionate

TES

Teslen

Testamone 100

Testandrone

Testaqua

Testiculosterone

Testim

Testim (TN)

Testobase

Testoderm

Testoderm Tts

Testogel

Testoject-50

Testolin

Testopel Pellets

Testopropon

Testosteroid

Testosteron

Testosterona

Testosterona [INN-Spanish]

testosterone

Testosterone

Testostérone

Testosterone (JAN/USP)

Testosterone [Androgenic steroids, anabolic]

Testosterone [INN:BAN]

Testosterone and its esters

Testosterone Cypionate

Testosterone Enanthate

Testosterone hydrate

Testosterone Hydrate

Testosterone solution

Testosteronum

Testosteronum [INN-Latin]

Testostosterone

Testoviron

Testoviron Schering

Testoviron T

Testred

Testred Cypionate 200

Testrin-P.A

Testro Aq

Testro AQ

Testrone

Testryl

trans-Testosterone

Trans-Testosterone

UNII-3XMK78S47O

Virilon

Virilon IM

Virormone

Virosterone

ZINC06500184

Ginkgo

Phase 2

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	A Multi-center, Double-blind, Placebo-controlled Study of Bupropion XL in Females With Orgasmic Disorder	Completed	NCT00248209	Phase 2, Phase 3	Wellbutrin XL
2	A Double Blind Placebo Controlled Trial of Autologous Platelet Rich Plasma (PRP) Peri-urethral and Clitoral Injections for the Treatment of Female Orgasmic Disorder	Unknown status	NCT03189238	Phase 2
3	Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction	Completed	NCT00034021	Phase 2	Ginkgo Biloba
4	A Placebo-Controlled, Randomized, Double-Blind, Parallel-Group, Dose-Finding Trial to Evaluate the Efficacy and Safety of TBS-2 Intranasal Testosterone Gel in Women With Acquired Female Orgasmic Disorder	Completed	NCT01607658	Phase 2	Placebo;Low dose TBS-2;Medium dose TBS-2;High dose TBS-2

Search NIH Clinical Center for Inhibited Female Orgasm

Sources

Genetic Tests for Inhibited Female Orgasm

Sources

Anatomical Context for Inhibited Female Orgasm

MalaCards organs/tissues related to Inhibited Female Orgasm:

⁴⁰

Breast

Sources

Publications for Inhibited Female Orgasm

Articles related to Inhibited Female Orgasm:

(show top 50) (show all 52)

#	Title	Authors	PMID	Year
1	Female Sexual Dysfunction: Pharmacologic and Therapeutic Interventions. ⁶¹	Wheeler LJ...Guntupalli SR	32541291	2020
2	The clitoral activation paradox - Claimed outcomes from different methods of its stimulation. ⁶¹	Levin RJ	29693269	2018
3	Toward a More Evidence-Based Nosology and Nomenclature for Female Sexual Dysfunctions-Part II. ⁶¹	Parish SJ...Whipple B	27843072	2016
4	Prevalence of Female Sexual Dysfunction Among Premenopausal Women: A Systematic Review and Meta-Analysis of Observational Studies. ⁶¹	McCool ME...Apfelbacher C	27871953	2016
5	A biopsychosocial approach to women's sexual function and dysfunction at midlife: A narrative review. ⁶¹	Thomas HN...Thurston RC	27013288	2016
6	The existing therapeutic interventions for orgasmic disorders: recommendations for culturally competent services, narrative review. ⁶¹	Salmani Z...Merghati-Khoei E	26494987	2015
7	Comparison of Elaeagnus angustifolia Extract and Sildenafil Citrate on Female Orgasmic Disorders: A Randomized Clinical Trial. ⁶¹	Akbarzadeh M...Sayadi M	25473627	2014
8	"Standard operating procedures for female orgasmic disorder" is not based on best evidence. ⁶¹	Brody S...Hess U	23578352	2013
9	Psychological and interpersonal dimensions of sexual function and dysfunction in women: An update. ⁶¹	Althof SE...Needle RB	26558096	2013
10	Characterization of orgasmic difficulties by women: focus group evaluation. ⁶¹	Kingsberg SA...Dickstein JB	23802867	2013
11	Correlation of question 15 of the FSDS-DAO with clinician evaluation of female orgasmic disorder. ⁶¹	Dickstein JB...Kreppner W	23782579	2013
12	Efficacy of psychological interventions for sexual dysfunction: a systematic review and meta-analysis. ⁶¹	Fruhauf S...Barth J	23559141	2013
13	Sexual dysfunction in young women with breast cancer. ⁶¹	Kedde H...Wijsen C	22714701	2013
14	Standard operating procedures for female orgasmic disorder: consensus of the International Society for Sexual Medicine. ⁶¹	Laan E...International Society for Sexual Medicine	22970851	2013
15	Psychometric Validation of the Sexual Function Questionnaire in Poland. ⁶¹	Slaski S...Stefankiewicz M	22363092	2012
16	The effect of major depression on sexual function in women. ⁶¹	Fabre LF...Smith LC	21883948	2012
17	Female orgasm rates are largely independent of other traits: implications for "female orgasmic disorder" and evolutionary theories of orgasm. ⁶¹	Zietsch BP...Martin NG	21569216	2011
18	Breast cancer treatment and sexual dysfunction: Moroccan women's perception. ⁶¹	Sbitti Y...Errihani H	21668971	2011
19	Application of the sexual health model in the long-term treatment of hypoactive sexual desire and female orgasmic disorder. ⁶¹	Robinson BB...Raymond NC	20878225	2011
20	Female sexual disorders: assessment, diagnosis, and treatment. ⁶¹	Kingsberg SA...Knudson G	24725342	2011
21	Female orgasmic disorder. ⁶¹	Rellini AH...Clifton J	22005203	2011
22	Disorders of orgasm in women: a literature review of etiology and current treatments. ⁶¹	Ishak WW...Bakhta Y	20584112	2010
23	The DSM diagnostic criteria for female orgasmic disorder. ⁶¹	Graham CA	19784768	2010
24	Women's sexual desire and arousal disorders. ⁶¹	Brotto LA...Luria M	20092454	2010
25	Emotional intelligence and its association with orgasmic frequency in women. ⁶¹	Burri AV...Spector TD	19453897	2009
26	Evaluation and treatment of female sexual disorders. ⁶¹	Kingsberg S...Althof SE	19440781	2009
27	Normal variations in personality are associated with coital orgasmic infrequency in heterosexual women: a population-based study. ⁶¹	Harris JM...Spector TD	18331253	2008
28	Pharmacologic treatment strategies for sexual dysfunction in patients with epilepsy and depression. ⁶¹	Stimmel GL...Gutierrez MA	16871136	2006
29	Prevalence and comorbidity of sexual dysfunctions in a Portuguese clinical sample. ⁶¹	Nobre PJ...Gomes FA	16418107	2006
30	Reliability and validity of the Sexual Interest and Desire Inventory-Female (SIDI-F), a scale designed to measure severity of female hypoactive sexual desire disorder. ⁶¹	Clayton AH...Wunderlich GR	16418104	2006
31	Behavioral assessment of couples' communication in female orgasmic disorder. ⁶¹	Kelly MP...Turner CM	16418102	2006
32	Validation of the McCoy Female Sexuality Questionnaire in an Italian sample. ⁶¹	Rellini AH...Meston CM	16362248	2005
33	The use of the sexual function questionnaire as a screening tool for women with sexual dysfunction. ⁶¹	Quirk F...Symonds T	16422841	2005
34	Disorders of orgasm in women. ⁶¹	Meston CM...Sipski M	16422985	2004
35	The meaning of heterosexual intercourse among women with female orgasmic disorder. ⁶¹	Birnbaum GE	12597273	2003
36	Validation of the Female Sexual Function Index (FSFI) in women with female orgasmic disorder and in women with hypoactive sexual desire disorder. ⁶¹	Meston CM	12519665	2003
37	Sildenafil citrate for female orgasmic disorder. ⁶¹	Gamble J...Menzies R	12085688	2002
38	Gender, sexual dysfunctions, and the Journal of Sex & Marital Therapy. ⁶¹	Winton MA	11441517	2001
39	Prevalence of sexual dysfunctions: results from a decade of research. ⁶¹	Simons JS...Carey MP	11329727	2001
40	Sildenafil in the treatment of female sexual dysfunction induced by selective serotonin reuptake inhibitors. ⁶¹	Shen WW...Clayton DO	10394548	1999
41	Definition and classification of female sexual disorders. ⁶¹	Leiblum SR	9647970	1998
42	Sexual dysfunction in treated breast cancer patients. ⁶¹	Barni S...Mondin R	9093723	1997
43	[Anorgasmic women]. ⁶¹	Raboch J...Raboch J	1823300	1991
44	Treatment acceptability of alternative sex therapies: a comparative analysis. ⁶¹	Wilson GL...Wilson LJ	2072403	1991
45	Incidence and prevalence of the sexual dysfunctions: a critical review of the empirical literature. ⁶¹	Spector IP...Carey MP	2205172	1990
46	Inhibited female orgasm resulting from psychotropic drugs. A five-year, updated, clinical review. ⁶¹	Shen WW...Sata LS	2405155	1990
47	Antidepressants and inhibited female orgasm: a literature review. ⁶¹	Jani NN...Wise TN	3066913	1988
48	Psychiatric drugs and inhibited female orgasm. ⁶¹	Segraves RT	2902230	1988
49	The epidemiology of the DSM-III psychosexual dysfunctions. ⁶¹	Nathan SG	3493350	1986
50	Inhibited female orgasm as a side effect of alprazolam. ⁶¹	Sangal R	2863987	1985

Sources

Genes for Inhibited Female Orgasm

Genes related to Inhibited Female Orgasm (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	IDH3G	Isocitrate Dehydrogenase (NAD(+)) 3 Non-Catalytic Subunit Gamma	Protein Coding	6.61	DISEASES inferred ¹⁵
2	IDH3A	Isocitrate Dehydrogenase (NAD(+)) 3 Catalytic Subunit Alpha	Protein Coding	6.24	DISEASES inferred ¹⁵
3	SHBG	Sex Hormone Binding Globulin	Protein Coding	5.89	DISEASES inferred ¹⁵
4	EHD4	EH Domain Containing 4	Protein Coding	5.48	DISEASES inferred ¹⁵
5	PRL	Prolactin	Protein Coding	5.13	DISEASES inferred ¹⁵
6	RPS19BP1	Ribosomal Protein S19 Binding Protein 1	Protein Coding	5	DISEASES inferred ¹⁵

Sources

Variations for Inhibited Female Orgasm

Sources

Expression for Inhibited Female Orgasm

Search GEO for disease gene expression data for Inhibited Female Orgasm.

Sources

Pathways for Inhibited Female Orgasm

Pathways related to Inhibited Female Orgasm according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Pyruvate metabolism and Citric Acid (TCA) cycle ⁶⁵ Show member pathways Citric acid cycle (TCA cycle) ⁶⁵ Interconversion of 2-oxoglutarate and 2-hydroxyglutarate ⁶⁵ NAD phosphorylation and dephosphorylation ¹ Pyruvate metabolism ⁶⁵ Regulation of pyruvate dehydrogenase (PDH) complex ⁶⁵ TCA Cycle ¹	11.07	IDH3G IDH3A
2	Citrate cycle (TCA cycle) ³⁶ Show member pathways pyruvate decarboxylation to acetyl CoA ¹ superpathway of conversion of glucose to acetyl CoA and entry into the TCA cycle ¹ TCA cycle ¹ TCA Cycle and Deficiency of Pyruvate Dehydrogenase complex (PDHc) ¹	10.64	IDH3G IDH3A

Sources

GO Terms for Inhibited Female Orgasm

Biological processes related to Inhibited Female Orgasm according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	tricarboxylic acid cycle	GO:0006099	8.96	IDH3G IDH3A
2	isocitrate metabolic process	GO:0006102	8.62	IDH3G IDH3A

Molecular functions related to Inhibited Female Orgasm according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor	GO:0016616	9.16	IDH3G IDH3A
2	NAD binding	GO:0051287	8.96	IDH3G IDH3A
3	isocitrate dehydrogenase (NAD+) activity	GO:0004449	8.62	IDH3G IDH3A

Sources

Sources for Inhibited Female Orgasm

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia